Denmark
Nordic Bioscience, founded in 1991, is a pioneering force in extracellular matrix (ECM) research, specializing in biomarker development to bolster preclinical and clinical trial results. Headquartered in Denmark, the company capitalizes on over three decades of experience to offer specialized laboratory services that cater to some of the world's leading pharmaceutical companies.
The firm’s proprietary Nordic ProteinFingerPrint Technology™ advances precision medicine by developing blood-based biomarker assays, which play a significant role in predicting disease activity and treatment responsiveness. Through these assays, Nordic Bioscience enables faster drug development and enhances the effectiveness of treatments for chronic conditions across various therapeutic areas, including cardiology, oncology, and rheumatology.
With a workforce exceeding 220 experts, the company maintains its competitive edge through high-quality operations, evidenced by its CAP accreditation, CLIA certification, and ISO9001 compliance. The last investment round was a $100.00M Private Equity Round led by Kohlberg Kravis Roberts in March 2021, highlighting the robust investor confidence in its groundbreaking approach to health care innovations.
PrecisionLife
